Michaela Lysakova-Ivanova

Analyst

Michaela is an Analyst at PRMA Consulting, having joined as a Market Access Intern.

She gained experience working on systematic literature reviews and is a member of the PRMA Tracker® team.

She recently completed her Masters at the LSE in International Health Policy and wrote her dissertation on the evidence requirements for digital therapeutics in the EU-5.

Michaela also holds a BA(Hons) in Global Health and Social Medicine from KCL.

In her spare time, Michaela enjoys running, traveling, and exploring new places with her friends and dog.

The insights you need to get the inside edge

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Welcoming Lewis Ruff, Senior Director, Global HEOR, within our policy, access, value, and evidence capability

Adapting to Change: Strategies for Pharma Service Providers, CROs, and R&D Partnerships in the Era of the Inflation Reduction Act

Forecasting global value assessments for a rare-disease drug

Welcoming Tyler Piazza, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability

Welcoming Caroline Solon, Senior Director Global Market Access, within our policy, access, value, and evidence capability

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (AAV)

Digital therapeutics: policy, access, value, and evidence

The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions

Value, Evidence, and Access: insights for markets outside of the EU5